The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Critical Outcomes Technologies

Monday Deal Review: September 16, 2013

 Welcome to your Monday Biotech Deal Review for September 16, 2013! The last week saw significant activity in financing. Of note is Miraculins $1,000,000 private placement, Sirona’s private placement, and Calyx’s proposal of a new private plcaement in response to the over-subscription of its previously announced offering. Finally, Stellar has raised $10 million in the initial closing of its own private placement.

In other news, Medicago is proceeding with its plan of arrangement after havign recieved court approval for the transaction.

See what else is happening in the biotech space by hitting the break!

Read more of this post

Monday Deal Review: September 31, 2012

Welcome to your Monday Biotech Deal Review for September 31, 2012. This week’s big news is yet another acquisition by Valeant, this time for the U.S rights and inventory of an age-related macular degeneration treatment from QLT Inc. Find more details on this story and others by clicking through.
Read more of this post

Monday Deal Review: September 17, 2012

Welcome to your Monday Biotech Deal Review for September 17, 2012. This week’s big news includes Valeant’s plans to syndicate an additional $1,000,000,000 of incremental term B loans, and Cangene’s sale of 3 plasma centres to U.S-based Grifols.  Read on to learn more.
Read more of this post

Monday Biotech Deal Review: May 9, 2011

Welcome to your Monday Biotech Deal Review for May 9, 2011.  Biotech activity was a bit slow last week.  Of note however is the minority shareholder oppression litigation launched against WEX Pharmaceuticals in the wake of the recent takeover by Pharmagesic (Holdings) Inc.  Read on to learn more.   Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 130 other followers